tiprankstipranks
Bluebird Bio to sell second Zynteglo PRV for $95M
The Fly

Bluebird Bio to sell second Zynteglo PRV for $95M

Bluebird Bio announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher, or PRV, for $95M. Bluebird bio was granted two PRVs upon the FDA approvals of Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, Bluebird closed the sale of its first PRV for $102M. Bluebird received a payment of $95M upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies acted as the exclusive financial advisor to bluebird for this transaction.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BLUE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles